Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (May 2014)
49 slides from Fluoropharma Medical's investor presentation, May 16, 2014
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
mere ee ue Aa Enabling Personalized Medicine Through Precision Diagnostics. (OTCQB:FPMI)
Slide 2: Forward-Looking Statements
Forward-Looking Statements Pharma This presentation contains "forward4ooking statements" within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the sa
Slide 3: Patients will die of heart disease
Patients will die of heart disease A cardiac perfusion scan is performed Portfolio of compounds in heart disease ~ CardioPET BFPET www.FluoroPharma.com
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Next generation molecular imaging drugs for diagnostic testing
Slide 5: Investment Highlights
Investment Highlights. Proprietary products that support new technologies for personalized medicine + Next generation / firstin-class diagnostic imaging + Helps determine the course of cardiac treatment Two Phase II-ready products with short study timelines, both directed to very large markets + BFP
Slide 6: BFPET Images
BFPET ImageseaeD BFPET's extremely high resolution allows the cardiologist to differentiate among ischemic, infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis, | Sestamibi Standard of Care | | BFPET | while BFP
Slide 7: Product programs: BFPET, CardioPET, VasoPET
and chronic ts that cannot undergo flow = 12 million potential patients = For use in combination with stress-testing in patients with presumptive chronic CAD = Toreplace SPECT in institutions with PET capability = Phase 2 (U.S., China) = Launch 2017 = USS. patent through 2025 Perfusion images * 17 m
Slide 8: Slide 8
Slide 9: Global Market for PET/SPECT (2010-2020)
Global Market for PET/SPECT (2010-2020) PET new unit sales projected to exceed SPECT by 2017 Pharma Global Market for PET/SPECT, 2040-2016, $bilons Coverall Global installed Bases of PET/SPECT Systems, 2010-2016 » (Govnest ao 5) Eas 10 6000 8 F 5000 : . 4000 000 ‘ 2000 2 ) 1000 ° a! 200 2011. 202 20
Slide 10: Substantial Installed Base in the US
Substantial Installed Base in the US Fluor — Pharma Cardiac stress tests are already performed more than 60% of the time at centers with PET machines. Distribution of PET Machines in US Hospitals, 2010+
Slide 11: PET Predicted to grow to 1/3 of U.S. nuclear cardiology procedures
PET Predicted to grow to 1/3 of Fluoro —— U.S. nuclear cardiology procedures Pharma Approximate Use of Cardiac Diagnostic Testing f} Future of Nuclear Cardiology in 2020 q 100% i f 90% 4 80% 8 i SPECT & ' SPECT/CT Q PET & PET/CT uonezuerpeo, Inwpeou, ‘oyog Seong se |noajoW/se9I0NN, q 0% 50% 100% ‘So
Slide 12: Production of Finished Material
Production of Finished Material US Cyclotron Distribution Network Approximately 100 FDG production sites (Cardinal Health, IBA, PETNET) will allow FluoroPharma to provide a high level of customer service, enabling product delivery within two to three hours to 85% of PET institutions nationwide. @ IG
Slide 13: Why PET now
Why PET now: Fluoro Distribution, infrastructure and increased install base Pharma + PET has a significantly higher rate of specificity and sensitivity than SPECT TICS WSS) + Leads to decreased attenuation artifacts and fewer inconclusive studies os JaulTIW 9) + provides a more accurate diagnosis fo
Slide 14: Large, Growing Market for Imaging Agents
Large, Growing Market for Imaging Agents. * Global market projected to exceed $15 billion by 2015 Imaging Drug Market + Fueled by need for personalized medicine + Additional drivers include: Growing volume of diagnostic examinations $78 Total 3 | and equipment sales. Advanced imaging agents in devel
Slide 15: Product Portfolio Market Size and Revenue Opportunity
Product Portfolio Market Size and Revenue Opportunity BFPET CardioPET VasoPET 12.0m 17.4m 555m. 30-50% 30-50% 1.5% 0.9m - © 40-90% 7 21-41% - 100% 1.45.4m 1.3-3.6m 0.9m $600 $600 $600 “$09328 = $08228 = ——$810M Se ee nw ferCes Pan ond Aosoninal om Unted Staten 2900-2008 NOMS Osta re Na 43 September
Slide 16: BFPET Clinical Use
Fluoro — BFPET Clinical Use Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress, CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (e.g. MIBI, tetrophosmin, T+201) or Rb
Slide 17: BFPET Phase I Trial Findings
BFPET Phase | Trial Findings ults show nt perfusion imaging properti * Rapid extraction from blood * Stable heart uptake over time : + High target to background ratios tency seviear.cregesroet Gametime we nan [pyeiliah y + Whole body effective dose: 73.5 + B 17.59 mrem/mCi + 42 healthy volunteers ag
Slide 18: Slide 18
Slide 19: The BFPET Opportunity
The BFPET Opportunity Projected BFPET Scans 14 Est. 5% Year Revenue 124 $691 million Est, PET #0 st. Market Procedures iy -set Size on Myocardial 06 perfusion 12 million 3.6 million imaging on 02 co oo) Year 1 Year 3 Year 5 49 www.FluoroPharma.com
Slide 20: BFPET Images
BFPET ImageseaeD BFPET's extremely high resolution allows the cardiologist to differentiate among ischemic, infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis, | Sestamibi Standard of Care | | BFPET | while BFP
Slide 21: CardioPET Clinical Use
Fluoro —— CardioPET Clinical Use Pharma CARDIAC VIABILITY ASSESSMENT * Identify patients that may benefit from PCI or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT * Invasive coronary angiography CLINICAL NEED + 4.3 million diagnostic angi
Slide 22: Fatty acid analog that detects regions of metabolic insufficiency
Fatty acid analog that detects regions of metabolic insufficiency | TRIAL COMPLETE! (15 NHV and 6 CAD patients) * CardioPET promising safety with no AEs detected * Clinical findings consistent with MPI SPECT * Quality of CardioPET images substantially superior to MPI SPECT PH, | TRIAL ONGOING + Init
Slide 23: RIG
RIG Pert dynamic (AC)
Slide 24: Slide 24
Slide 25: The CardioPET Opportunity
The CardioPET Opportunity muuons Projected CardioPET Scans Po sssurtone ee Est. 5' Year Revenue $605 million 16 Est PET Est. FP aaa Procedures Market Size Share a2 CAD diagnosis aiagnesis—3.8million 4 milion 32% 08 Cardiac viability 4 § milion 0.5 million 80% o4 assessment Myocardial oo magne en Ta
Slide 26: VasoPET Indications and Clinical Use
Fluoro —— VasoPET Indications and Clinical Use Pharma EVALUATION OF + Patients with acute cardiac event or stroke (risk of recurring event) + Therapy following acute cardiac event or stroke (e.g, Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE + Clinical symptoms; several imaging
Slide 27: Detection Of Inflamed Atherosclerotic Plaque
Fluoro Detection Of Inflamed Atherosclerotic Plaque Pharma WHY INFLAMMATION IMAGING? a met * Diagnosis before symptoms occur * Crucial role at all stages of atherosclerosis + May aid drug development DEVELOPMENT STATUS. + Preclinical testing completed + IND preparation ongoing vt * Plan to initiate
Slide 28: Clinical drivers Advancing the Transition to PET in Clinical Cardiology
Clinical drivers Advancing the Transition to PET in Clinical Cardiology Drivers and Benefits: por ag dn Net Cag @ iansion ofetinicalindications/ctinical needs maeing tna a my ED ng eT tree Lower radiation dose = Improved diagnostic accuracy Improved patient outcomes: Soe eas Qtr aesenmneenere nearer
Slide 29: Experienced Management Team and Advisors
Experienced Mar Fluoro nagement Team and Advisors Pharma | H, William Strauss, MD Daniel Berman, MD Peter Cont. MD, PhD Elazer Edelman, MD, PhD. Heinrich Schelbert, MD. Thijs Spoor President, CEO + Healthcare executive with >45 years medical industy experience + Foimer securities analyst at JP. Morg
Slide 30: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment + Myocardial perfusion imaging * Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing + Diagnostic alternativ
Slide 31: www.FluoroPharma.com
www.FluoroPharma.com 2
Slide 32: The Next Big Step in Healthcare
| Fluoro The Next Big Step in Healthcare MEDICINE TODAY One treatment fits all - =» still a guessing game www.FluoroPharma.com 2
Slide 33: Personalized Diagnosis
Personalized Diagnosis. MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome x: Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis www.FluoroPharma.com 2
Slide 34: Unmet Need for Better Imaging Methods
Unmet Need for Better Imaging Methods FDA Warning in 2007 + Nephrogenic systemic fibrosis for Gadolinium-based contrast agents a Ultrasound ANATOMICAL L FDA Warning in 2007 IMAGING > * Deaths and serious cardiopulmonary reactions arising from marketed products None of these capture physiology - Fluo
Slide 35: PET Imaging Roots are in Oncology
PET Imaging Roots are in Oncology PET procedures by disease area 2500 g 700 3 Cardiology = 1500 and § |, neurology 8 remain & 1000 strong growth 5 opportunities 500 2004 2005 2006 2007 2008 2008 Year Oncology Ml Neurology lll Cardiology Source. Fost &Sullvan 2008 www.FluoroPharma.com 2
Slide 36: Cardiovascular Disease is the Next Big Opportunity
Pharma Cardiovascular Disease is the Next Big Opportunity Total diagnostic radiopharmaceutical agents market: Cardiac imaging procedures are the greatest opportunity to switch to PET 25 , Procedures a6 (millions) Cy, 21.3 CAGR 20.4 204 4 18.9 J] “07-09 PET (Total) 17.0% SPECT (Cardiac) 7.3% SPECT (O
Slide 37: Technical Trends - Growth drivers enabling shift in technology
Technical Trends - Growth drivers enabling shift in technology Fluoro Technical and Diagnostic Benefits of PET vs. SPECT Pharma + Improved overall image quality + Dynamic tomographicimaging + High Definition Hybrid imaging: calcium scoring, CT angiography + Improved spatial, temporal and contrast re
Slide 38: FluoroPharma Enables Personalized Diagnosis
Fluoro —— FluoroPharma Enables Personalized Diagnosis Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment Spatial Temporal Contrast Resolution Resolution Resolution Method Allows direct visual evaluation of disease on a molecular level + Measures the
Slide 39: Poised to Capture Cardio Diagnostics
Fluoro —— Poised to Capture Cardio Diagnostics Pharma + Lin-3 adults have some form of CV + Superior image quality disease + PET isa large and rapidly growing + $403 billion: fully burdened cost of imaging platform CAD + Increasing demand for PET + ~42 million CV nuclear sans (MPI) in technology in
Slide 40: Robust Portfolio On-Track
Fluoro Robust Portfolio On-Track Pharma Market | Patients. Drug/ Indication Patent | Licens | Pre | IND u uw NDA e — olinical $08-228 174M $093.28 120M soi sssm I que coronary Carotid coronary perforation ie plaque carotid Soucs compan Aion & estate, FuoPorms enarha exis, han eros Emerge Operon Vs f
Slide 41: The VasoPET Opportunity
The VasoPET Opportunity muons Projected VasoPET Scans mpti 08 Est. 5!" Year Revenue ar $408 million 06 Market Patients St PET Mit We Size 7 om 04 ‘oreening for athe Ris S0million 300,000 ao Response to 3.8 million 380,000 02 therapy (statins) o4 Follow-up after 0 09million 90,000 heartattack Year 1
Slide 42: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare Medical
Slide 43: Molecular Imaging
Molecular Imaging Radio- Pharmaceutical Distribution Eli Lily. Bracco: emens, PETNET Phill Development Multiple players in each value chain www.FluoroPharma.com
Slide 44: The cycle of classic medicine is reactive medical care
Fluoro —— The cycle of classic medicine is reactive medical care Pharma Reactive Medical Care Disease Severity Degree Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment 44 alized Medicine Coaliton, Abrahams Presentation www.FluoroPharma.com
Slide 45: Shifting to outcomes focused personalized treatments increases efficiency
Shifting to outcomes focused personalized treatments increases efficiency Efficient Medical Care Disease Severity Health Management; Molecular Screening; Early Detection; Rapid Effective Treatment; Improved Quality of Care 45 Personalized Medicine Coalition, Abrahams Presentation www.FluoroPharma.co
Slide 46: Cardiovascular Disease
F Fluoro —— Cardiovascular Disease Pharma KEY FACTS - US AND WW. WHO: “Neglected Global Epidemic” 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. 1/3 of deaths in China, ¥2 in Europe + 2.4M deaths US: top cause (38.5%) KEY UNMET NEEDS * CAD: Get closer to the disease sour
Slide 47: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints Pharma conomic pressures PAST FUTURE Fragmented, oD wv 5 BS a B Integrated, non-systems systems of Grea Decisions byjindividual|stakeholders: =| care Ss | delivery =——___ Decisions by advanced stakeholder networks § (il) Aligned inant HCP type Sol
Slide 48: Market Drivers for New PET Products
Market Drivers for New PET Products _~ Pharma Growth in PET Low capacity Comprehensive adoption of early procedural volumes utilization diagnosis will improve utilization of technology At capacity, more patients could be 74 diagnosed earlier leading to better patient see) outcomes. 6 Unutlized J ¥ *
Slide 49: Thank you for listening!
F luego a aaa Thank you for listening!
FluoroPharma Medical — Investor Presentation (May 2014) on 6ix